Table 2 Results of logistic regression of buprenorphine adoption on facility and state characteristics
From: State policy influence on the early diffusion of buprenorphine in community treatment programs
| Â | B | 95% CI | OR |
|---|---|---|---|
Ownership/Profit Status a | Â | Â | Â |
Government owned | -.457* | (-.833, -.082) | .63 |
Private, non-profit | -.605** | (-.827, -.384) | .55 |
Facility Characteristics | Â | Â | Â |
Based in a hospital | .671** | (.411, .931) | 1.96 |
Opioid Treatment Program (OTP) | .696** | (.276, 1.115) | 2.00 |
SA treatment is primary focus | .014 | (-.332, .359) | Â |
Offers detox | 1.959** | (1.545, 2.374) | 7.09 |
Outpatient only | -.186* | (-.343, -.028) | .83 |
Adolescent program | -1.123** | (-1.667, -.581) | .33 |
Accredited | .307** | (.114, .500) | 1.36 |
Past-year admissions | .0002** | (.0001, .0003) | 1.00 |
Located in a metropolitan area | .541** | (.243, .838) | 1.72 |
Key Funding Sources | Â | Â | Â |
Receives government funds | -.306** | (-.515, -.098) | .74 |
Accepts Medicaid | .175 | (-.110, .460) | Â |
Has managed care contract(s) | .472** | (.280, .665) | 1.60 |
State-Level Variables | Â | Â | Â |
SSA encourages use of buprenorphine | .171 | (-.098, .440) | Â |
Medicaid covers buprenorphine | .081* | (.011, .152) | 1.09 |
McKelvey & Zavonia's R2 | .364 | Â | Â |
Model chisq (df) p | 778.51 (16) p < .001 | Â | Â |